Amber Svardal MSN, RN, OCN doesn’t just talk about innovation, she puts it into practice every day! From sorting through massive medical congress agendas to helping teams uncover key insights, Amber leverages AI in new and creative ways when tackling complex tasks – creating more time for meaningful conversations and smarter decision-making. Thank you, Amber, for always leading with curiosity and a constant desire to improve how we work! This is Purpose in Action: real people, real work, and real impact – happening every day across EVERSANA. Discover the EVERSANA difference: https://ow.ly/OLa550YZ6mQ #AI #LifeSciencesInnovation #AlwaysInnovate #EVERSANA #PurposeInAction
About us
EVERSANA® is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com.
- Website
-
http://eversana.com
External link for EVERSANA
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, IL
- Type
- Privately Held
- Specialties
- Regulatory, Management & Specialty Consulting, Research & Insights, Global Pricing Strategies, Patient, Payer & Provider Marketing Services, Field Medical, Market Access & Sales , Global Channel Management & 3PL, Specialty Pharmacy & In-Home Nursing, HUB & Adherence Solutions, Affordability Programs, Medical Communications & Pharmacovigilance, Revenue Management, Digital Strategies & Therapy Transformation, Patient Analytics Services, Integrated Patient-Level Data, Commercial Analytics Platform, RWE & HEOR Global Services, Global Launch Expertise, and Payer Reimbursement Strategies
Locations
Employees at EVERSANA
Updates
-
The future of pharma pricing and market access unfolds at PPIC 2026, June 9–11, in Basel, Switzerland. Join global leaders, policymakers, and industry experts for practical insights and open discussion on the policy, reimbursement, and access dynamics shaping pharmaceutical strategy across markets. Explore the preliminary agenda and register now: https://lnkd.in/ehgcY_i2
-
-
Members of our team are excited to attend #BIO2026. BIO International is where innovation meets opportunity. We’re looking forward to connecting with biopharma leaders to discuss how our integrated commercial partnerships help turn promising science into predictable, scalable success. Interested in reducing risk and strengthening enterprise value while maintaining control and flexibility? Schedule time to connect and learn how: https://ow.ly/6Z6I50YMUbz
-
“Access” is no longer just a benefit — it’s a strategic lever. As employers face rising demand for GLP‑1 therapies, new direct‑to‑employer models are emerging to reduce complexity and improve outcomes. Deanna Horner shares what’s changing and what it means for the future of care. Read more https://lnkd.in/dXnw5dTA Waltz Health #HealthcareAccess #GLP1 #Commercialization #LifeSciences
-
The instinct to build AI in-house is understandable. The harder question is whether that path accelerates impact or quietly slows it down. See the full perspective: https://lnkd.in/dKr4Fe3j #LifeSciences #AIInPharma
-
-
Is your EU launch strategy at risk? A single PICO misalignment for the new Joint Clinical Assessment can lead to costly delays and rework. The question is no longer if you should predict the PICO, but how. Is AI, a literature review, or a survey the right tool? In ISPOR’s Value & Outcomes Spotlight feature, EVERSANA experts Pamela V. and Shivani Shah, alongside industry experts, explore why a blended, tailored strategy is the only practical path forward. Navigate the JCA with confidence. Read the full article: https://ow.ly/cJPV50YVJnM
-
If a biotech is looking to out-license, is Phase 3 really the right time? Our experts analyzed five years of late-stage and post-approval licensing deals and uncovered powerful insights about valuation, deal frequency, upfront cost, and probability of growth. Get the full analysis here: https://ow.ly/6NsK50YIc4Y
-
-
At Asembia 2026, the conversation has shifted. Patient access is now a competitive differentiator. AI is moving from hype to real use cases. And integrated commercialization models are becoming essential. KRISTA PINTO shares what she’s hearing from the market with pharmaphorum. Read more https://lnkd.in/dcsnfUas #Asembia #PharmaLeadership #LifeSciencesInnovation
-
Nearly one year after the MFN executive order, clear patterns are emerging across global pricing and access. Data from the NAVLIN Insights’ MFN Tracker reveals: • Higher launch prices in parts of Europe compared to the U.S. • Persistent pricing gaps in markets like Japan • Increasing variability in ex-U.S. launch timelines • Emerging trade-offs between speed to launch and U.S. price protection Together, these signals point to a more complex and strategic global landscape than initially anticipated. Explore the full insights: https://ow.ly/1qsN50YXFzq Alan Crowther, Gustav Ando, Charles Moun Goun Gou
-
From early strategic planning through post‑launch execution, Ashish Saini, PhD, Senior Principal, Integrated Analytics, supports our clients at every stage of the commercial journey. Ashish’s deep knowledge of real-world data assets and dedication to operational excellence sets him apart – and earns consistent praise from partners who credit him as key to their success. Thank you, Ashish, for relentlessly pursuing strong partnerships and building trust every day! This is Purpose in Action: real people, real work, and real impact – happening every day across EVERSANA. Discover more about our beliefs and how you could become part of the EVERSANA Difference: https://ow.ly/mZl250YXOwY #IntegratedAnalytics #LifeSciencesCommercialization #ClientDelight #EVERSANA #PurposeInAction